Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
| Software Industry | Information Technology Sector | Bryan C. Hanson CEO | XMEX Exchange | US83444M1018 ISIN |
| US Country | 20,000 Employees | - Last Dividend | - Last Split | - IPO Date |
Solventum Corporation is a cutting-edge healthcare company established in 2023 and headquartered in Saint Paul, Minnesota. Specializing in the development, manufacture, and commercialization of diverse solutions aimed at addressing urgent customer and patient needs, the company operates across four main segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Solventum Corporation stands out in the healthcare industry by offering a wide-ranging portfolio of innovative products and services, demonstrating its commitment to improving healthcare outcomes and enhancing the efficiency of medical and dental professions.